Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase 1/2 4

Status

Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × guadecitabine × Clear all
NCT02935361 2026-01-29

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

University of Southern California

Phase 1/2 Active not recruiting
33 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03308396 2022-02-17

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03576963 2021-04-05

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

University of Southern California

Phase 1/2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT01896856 2020-10-06

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
118 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡